Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Fig. 6

Prediction of TF binding to rs822336 based on allele-specificity. The output of the analysis contains the TFs [database accession number] predicted with a dissimilarity margin less or equal than 15% to the target sequence +/−25 bp to rs822336 G (A) and C (B) genotype. Nucleotide sequence of the potential binding site as well as the position of each TFBS are illustrated. Tables report a detail of the serum response factor (SRF) binding site prediction and the random expectation (RE) values for different levels of sequence-matrix similarity. The rate of dissimilarity between the putative and consensus sequences for TFs is indicated; RE indicates expected occurrences of the match in a random sequence of the same length as the query sequence according to the dissimilarity index based on equi–probability for the four nucleotides (RE equally) and nucleotide frequencies in the query sequence (RE query). NFI/CTF [T00094] also known as Nuclear Factor I C (NFIC)

Back to article page